- Tradjenta® (linagliptin) demonstrated similar long-term cardiovascular safety compared with placebo in adults with type 2 diabetes
- The overall safety profile of Tradjenta in the trial, including adults with kidney disease, was consistent with previous data and no new safety signals were observed
- The results of CARMELINA® were presented at the 54th EASD Annual Meeting today
PR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018